Strides Pharma Science · NSE: STAR · BSE: 532531

Q2 FY21 results · Jul–Sep 2020

Strides Pharma Science reported revenue from operations of ₹793.56 crore (up 11.0% from Q2 FY20) and net profit of ₹76.99 crore (down 45.8% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY21	Q2 FY20	YoY	Q1 FY21	QoQ
Revenue from operations	793.56	715.09	+11.0%	781.80	+1.5%
Other income	12.87	12.99	−0.9%	12.30	+4.6%
Total income	806.43	728.08	+10.8%	794.10	+1.6%
Profit before share of associates & JVs and tax	98.44	161.68	−39.1%	126.08	−21.9%
Share of profit/(loss) of associates & JVs	(30.12)	(21.25)		(20.96)
Net profit for the period	76.99	141.91	−45.8%	101.84	−24.4%
Attributable to shareholders of the company	80.94	142.72	−43.3%	103.56	−21.8%
EPS, basic (₹)	9.03	15.94	−43.4%	11.56	−21.9%
Net margin (%)	9.7	19.8		13.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY21	Q2 FY20	YoY	Q1 FY21	QoQ
Revenue from operations	384.33	425.41	−9.7%	409.34	−6.1%
Other income	38.54	32.20	+19.7%	15.33	+151.4%
Total income	422.87	457.61	−7.6%	424.67	−0.4%
Profit before tax	19.20	58.22	−67.0%	6.14	+212.7%
Net profit for the period	13.68	47.00	−70.9%	4.16	+228.5%
EPS, basic (₹)	1.53	5.25	−70.9%	0.46	+232.6%
Net margin (%)	3.6	11.0		1.0

Consolidated

Filed with BSE: 30 Oct 2020, 12:35 IST
Board meeting: 29 Oct 2020
Period: 01 Jul 2020 to 30 Sep 2020
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 30 Oct 2020, 12:35 IST
Board meeting: 29 Oct 2020
Period: 01 Jul 2020 to 30 Sep 2020
Review status: Unaudited
Source: XBRL filing on BSE